Results 161 to 170 of about 142,411 (263)

Genomic variant profiling in blast‐phase paediatric chronic myeloid leukaemia: Predisposing and driving alterations

open access: yesBritish Journal of Haematology, EarlyView.
To identify pathogenic somatic and germline gene variants associated with blast‐phase transformation and cancer predisposition in paediatric chronic myeloid leukaemia (CML), n = 19 patients with blast‐phase paediatric CML were analysed with whole genome and targeted panel sequencing and compared to n = 19 patients with chronic phase paediatric CML.
Yvonne Lisa Behrens   +22 more
wiley   +1 more source

Anaplastic large cell lymphoma in children and adolescents

open access: yesBritish Journal of Haematology, EarlyView.
Summary Anaplastic lymphoma kinase (ALK)‐positive anaplastic large‐cell lymphoma (ALCL) accounts for >95% of ALCL cases in children and adolescents. The first description of ALCL as a CD30‐positive lymphoma in 1985 was followed by the detection of chromosomal translocations involving the ALK gene at chromosome 2p23.
Eric J. Lowe, Wilhelm Woessmann
wiley   +1 more source

Real‐world clinical experience with NGS‐based chimerism analyses in haematopoietic stem cell transplant patients

open access: yesBritish Journal of Haematology, EarlyView.
This study demonstrates the clinical utility of a next‐generation sequencing (NGS)‐based chimerism assay (CASAL) in haematopoietic stem cell transplantation (HSCT). Compared to conventional short tandem repeat (STR) methods, CASAL showed significantly higher marker informativeness, detecting mixed chimerism (MC) below 5% recipient DNA with a median of ...
Jin Ju Kim   +7 more
wiley   +1 more source

Temporal patterns in US population‐based patient survival among adults treated with chemotherapy and/or immunotherapy for multiple myeloma, 2000–2020

open access: yesBritish Journal of Haematology, EarlyView.
Summary Few population‐based studies have rigorously evaluated overall survival (OS) differences among adults treated with chemotherapy and/or immunotherapy (chemo/immunotherapy) for multiple myeloma (MM) during the past two decades when the therapeutic landscape substantially evolved.
Graça M. Dores   +7 more
wiley   +1 more source

Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: A 20‐year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT)

open access: yesBritish Journal of Haematology, EarlyView.
We report the UK experience of autologous haematopoietic stem cell transplantation (AHSCT) for multiple sclerosis (MS) in 364 patients. In our observational study, transplant‐related mortality was 1.4%, Epstein–Barr virus reactivation occurred in 75.9%, while disability progression‐free survival was 83.5% at 2 years post‐AHSCT and 62.4% at 5 years.
Majid Kazmi   +18 more
wiley   +1 more source

The anti‐CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B‐cell lymphomas

open access: yesBritish Journal of Haematology, EarlyView.
Follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL) are characterized by a continuous incidence of relapse and increasing resistance to therapy. Novel immunotherapy approaches are needed.
Rahul Lakhotia   +11 more
wiley   +1 more source

Patients With Atopic Dermatitis Show Increased Clonal Hematopoiesis and Risk of Hematological Cancer

open access: yes
Allergy, EarlyView.
Verena Vogi   +6 more
wiley   +1 more source

Protein tyrosine phosphatases as emerging targets for cancer immunotherapy

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Contemporary strategies in cancer immunotherapy, despite remarkable success, remain constrained by inherent limitations such as suboptimal patient responses, the emergence of drug resistance, and the manifestation of pronounced adverse effects. Consequently, the need for alternative strategies for immunotherapy becomes clear.
Zihan Qu, Jiajun Dong, Zhong‐Yin Zhang
wiley   +1 more source

GPCR‐G protein signalling and its mutational landscape in cancer—Driver or passenger

open access: yesBritish Journal of Pharmacology, EarlyView.
G protein‐coupled receptors (GPCRs) play a crucial role in cellular signalling, regulating various physiological processes. Abnormal expression and mutations of GPCRs have been implicated in several types of cancer, influencing tumour initiation, progression and immune response.
Chenlin Feng   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy